GINKGO BIOWORKS HOLDINGS INC

DNA is the ticker symbol for Ginkgo Bioworks Holdings, Inc., a company that operates a biotechnology platform for cell programming. The stock trades on the New York Stock Exchange. Ginkgo uses genetic engineering to design custom microorganisms for customers across industries such as healthcare, agriculture, and materials. DNA stock represents an ownership stake in this synthetic biology company, which focuses on enabling partners to develop bio-based products and solutions.

DNA's stock price can be influenced by several factors, including the company's revenue growth, earnings results, and progress in expanding its cell programming platform. Broader biotechnology sector trends, investor sentiment toward speculative growth stocks, and changes in government funding for synthetic biology can also play a role. Additionally, news about partnerships, contract wins, or regulatory developments may impact the stock. Macroeconomic conditions like interest rates and inflation can affect valuation multiples for growth-oriented companies.

Recent performance for DNA stock depends on the latest market data, which changes daily. To see how the stock has performed over the past days, weeks, or months, please refer to the current price chart and performance metrics displayed on this page. These tools provide up-to-date information on DNA's price movements, trading volume, and percentage changes over various time frames.

You can find the latest DNA stock price on this page, which displays real-time or delayed quotes depending on the data feed. The page typically includes the current price, daily change, bid and ask, and trading volume. For the most accurate and up-to-date information, refresh the page or check a live market data provider. Always verify prices through official exchange data or your brokerage platform before making trading decisions.

Evaluating DNA's valuation involves analyzing metrics such as price-to-sales (P/S) and price-to-book (P/B), since the company may not have consistent earnings. Compare these ratios to industry peers and consider growth prospects, profitability timelines, and cash flow. Because Ginkgo is a growth-stage company, traditional P/E may not be meaningful. Review the financial statements and forward estimates to assess whether the market price reflects future potential. Current valuation metrics are available on this page.

Key risks for DNA include the possibility that its technology platform may not achieve commercial success or generate sustainable revenue. The company faces competition from other synthetic biology firms and traditional methods. Additionally, DNA may require significant capital to fund research and development, and could be impacted by changes in government regulations or funding. As a growth-stage company, its stock price can be volatile, and it may not pay dividends. Investors should review the company's risk factors in its SEC filings for a comprehensive list.